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Patients with cancer are more prone to develop venous 
thromboembolism (VTE), due to the hypercoagulable 
state caused by the malignancy, but also to other additive 
risk factors, such as mechanical injury of the venous endo­
thelium by the use of intravenous catheters and irritation 
of vessel walls by chemotherapy. In cancer patients who 
develop VTE the risk of death is more than threefold than in 
patients without cancer who have VTE [1–3] and in those 
with cancer but no VTE [4]. This high mortality rate is pro­
bably due to both the VTE and the fact that malignancies 
associated with VTE appear to follow a more aggressive 
course [4]. Thus, identifying clinical characteristics that 
put cancer patients at increased risk of VTE is important 
if their outcomes are to be improved.
Upper­extremity deep vein thrombosis (DVT) was 
long believed to be an uncommon disorder caused by 
malrotation of the upper extremity, especially when as­
sociated with strenuous exercise. However, with the in­
creasingly common use of intravenous catheters, arm 
DVT has been recognised as being more common than 
previously reported, but its frequency continues to be 
much lower than that of lower limb DVT. Accordingly, 
there is little information on the clinical characteristics 
and outcome of these patients.
The Informatised Registry on Venous Thromboem­
bolism (RIETE) was initiated in March 2001 to prospec­
tively record the current clinical management of VTE. 
It is an ongoing, multicenter, observational registry 
designed to gather and analyze data on treatment 
patterns and clinical outcomes in consecutive patients 
with symptomatic, objectively confirmed, acute VTE 
[5–9]. The aim of the present study was to identify 
the clinical characteristics and 3­month outcome of 
all cancer patients with upper­extremity deep venous 
thrombosis (DVT) enrolled in RIETE.
Patients and Methods
Consecutive patients with symptomatic, acute DVT 
or pulmonary embolism (PE), confirmed by objective 
tests are enrolled in RIETE. 
Variables. The parameters recorded by the registry 
comprise details of each patient’s baseline characteris­
tics; clinical status, including any coexisting or underlying 
conditions; cancer characteristics; the type, dose, and 
duration of treatment received on VTE diagnosis, and 
clinical outcome during the first 3 months of therapy. 
Clinical definitions. Immobilized patients are de­
fined in this analysis as non­surgical patients who had 
been immobilized (i. e., total bed rest with bathroom 
privileges) for ≥ 4 days in the 2­month period prior to 
VTE diagnosis. Surgical patients are defined as those 
who had undergone an operation in the 2 months prior 
to VTE diagnosis. Fatal PE was defined as any death 
occurring shortly (< 7 days) after PE diagnosis (either 
the initial episode or recurrent PE), in the absence of an 
alternative cause of death. Fatal bleeding was defined 
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as any death occurring shortly (< 7 days) after a major 
bleeding episode. Bleeding complications were classi­
fied as “major” if they were overt and were associated 
with a decrease in hemoglobin level of ≥ 2.0 g/dL, 
required a transfusion of ≥ 2 units of blood, or were 
retroperitoneal or intracranial. 
Follow-up. After hospital discharge, all patients 
were followed­up for at least 3 months. During each 
visit, any signs or symptoms suggesting either DVT or 
PE recurrence or bleeding complications were noted. 
Each episode of clinically suspected recurrent DVT or 
PE was documented by repeat compression ultraso­
nography, venography, lung scanning, helical CT scan 
or pulmonary angiography. 
Statistical analysis. Odds ratios and corresponding 
95% confidence intervals were calculated using Con­
fidence Interval Analysis software (version 2.0.0), and 
p < 0.05 was considered to be statistically significant. The 
significance of a number of clinical variables on the mor­
tality rate was tested by Chi­Square test for categorical 
variables and by t­test for numerical variables. Candidate 
variables were selected from clinical variables based on 
published literature and on expert opinion.
resUlts
Up to Febrary 2006, a total of 14,391 patients with 
symptomatic, objectively confirmed acute VTE had been 
enrolled in RIETE and followed­up for up to 3 months. 
Of the 2,945 patients with active cancer 196 (6.7%) 
had arm DVT. One hundred and four of them (53%) had 
catheter­associated DVT (central line 37, port system 
37, peripheral line 8, stent 6, pacemaker one).
Most cancer patients with arm DVT were males, 
younger than 65, and had a low incidence of additional 
risk factors or underlying diseases. Twenty of these 
patients (10%) had both clinical signs and objective 
diagnosis of PE. Most patients were treated with low­
molecular­weigh heparin, both initially (94%) and after 
discharge (75%). During the 3­month follow­up period 
12 patients (6.1%) developed VTE recurrences (PE 6, 
DVT 6), 8 (4.1%) had major bleeding (fatal in 3). 
Patients with catheter­associated DVT had more of­
ten a recent episode of surgery, and less often chronic 
lung disease than those with no catheter, as shown in 
the Table. Right­side DVT was more common in these 
patients. They had less often metastatic cancer, and 
appeared more commonly in patients with colorectal 
cancer, but less often in lung cancer. During follow­up, 
the rates of fatal PE, recurrent VTE, fatal bleeding and 
major bleeding were similar, but overall death was 
higher in patients with no catheter. 
discUssion
The data in this analysis, obtained from a large pro­
spective series of consecutively enrolled patients in the 
RIETE registry, confirm that arm DVT is an uncommon 
complication in patients with cancer compared to lower­
extremity DVT. There was a similar incidence in patients 
with or without catheter, and one in every 10 patients 
had concomitant PE. As for their clinical outcome, the 
6.1% incidence of recurrences and the 4.1% of major 
bleeding is similar to the reported rates in patients with 
lower limb DVT while on anticoagulation [10].
Table. Clinical characteristics and 3-month outcome of the 196 patients 
with cancer and upper-extremity DVT
Variables
Cathe­
ter 
N = 104
No 
catheter 
N = 92
Odds ratio 
(95% CI)
P 
value
Clinical characteristics,
   Gender (males)
   Age > 65 years
   Body weight < 70 kg
Underlying diseases,
 Creatinine levels > 1.2 mg/dL
   Chronic lung disease
   Chronic heart failure
Risk factors for VTE,
   Immobility ≥ 4 days
   Surgery < 2 months
   Prior VTE
Cancer characteristics,
   Metastatic cancer
   Site of cancer:
     Lung
     Breast
     Colorectal
     Stomach
     Haematological
     Other 
Clinical presentation,
   Symptomatic PE
   Left side DVT
   Bilateral DVT
Initial therapy,
   UFH
   LMWH
Long-term therapy,
   AVK drugs
   LMWH
3-month outcome,
   Major bleeding
   Fatal bleeding
   Recurrent DVT
   Recurrent PE
   Fatal PE
   Overall mortality
59 (57%)
39 (38%)
54 (52%)
11 (11%)
4 (3.8%)
2 (1.9%)
5 (4.8%)
29 (28%)
5 (4.8%)
51 (49%)
23 (22%)
13 (13%)
23 (22%)
11 (11%)
10 (9.6%)
24 (23%)
10 (9.6%)
35 (34%)
5 (4.8%)
3 (2.9%)
98 (94%)
23 (22%)
75 (72%)
4 (3.8%)
1 (1.0%)
4 (3.8%)
4 (3.8%)
1 (1.0%)
17 (16%)
63 (69%)
39 (42%)
46 (50%)
5 (5.4%)
12 (13%)
6 (6.5%)
8 (8.7%)
12 (13%)
8 (8.7%)
58 (63%)
32 (35%)
14 (15%)
5 (5.4%)
4 (4.3%)
5 (5.4%)
32 (35%)
10 (11%)
45 (50%)
10 (11%)
5 (5.4%)
87 (95%)
22 (24%)
63 (68%)
4 (4.3%)
2 (2.2%)
2 (2.2%)
2 (2.2%)
0
26 (28%)
0.6 (0.3–1.1)
0.8 (0.5–1.4)
1.1 (0.6–1.9)
2.1 (0.7–6.2)
0.3 (0.1–0.9)
0.3 (0.1–1.4)
0.5 (0.2–1.7)
2.6 (1.2–5.4)
0.5 (0.2–1.7)
0.6 (0.3–1.0)
0.5 (0.3–1.0)
0.8 (0.4–1.8)
4.9 (1.8–14)
2.6 (0.8–8.5) 
1.6 (0.6–5.6)
0.6 (0.3–1.1)
0.9 (0.3–2.4)
0.5 (0.3–1.0)
0.4 (0.1–1.4)
0.5 (0.1–2.6)
0.9 (0.2–3.6)
0.9 (0.4–1.8)
1.2 (0.6–2.3)
0.9 (0.2–3.6)
0.4 (0.1–4.9)
1.8 (0.3–10)
1.8 (0.3–10)
—
0.5 (0.2–1.0)
0.090
0.485
0.788
0.189
0.019
0.104
0.275
0.011
0.275
0.049
0.050
0.582
0.001
0.102
0.272
0.070
0.773
0.030
0.112
0.369
0.919
0.765
0.578
0.859
0.490
0.498
0.498
0.346
0.044
Traditionally, the significance of arm DVT has 
received less attention in comparison to lower extre­
mities DVT, probably due to the erroneous belief that 
accompanying or subsequent PE is rare. Accordingly, 
in the past several authors have questioned the need 
for anticoagulant therapy in such patients. However, 
recent prospective studies using sensitive methods for 
detecting PE have demonstrated that the prevalence 
of both symptomatic and asymptomatic PE in patients 
with arm DVT is high, and it is close to that observed in 
cohorts of patients with lower­extremity DVT [11–14]. 
One in every ten patients with arm DVT in our series had 
symptomatic PE, thus confirming these findings. 
The main limitation of this study lies on the likely un­
derestimated incidence rate of fatal PE after discharge. 
Certainly, death of some cancer patients at home or in 
long­term care facilities may have been due to PE, but 
these but may not have been labeled as induced by PE 
as the Adjudication Committee only accepts VTE events 
that have been objectively confirmed. On the other hand, 
in the RIETE registry selection bias was avoided by in­
cluding consecutive patients with objectively confirmed, 
symptomatic, acute VTE who were referred to study cen­
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ters. Enrolled patients were treated according to standard 
practice, and prospective follow­up was completed for 
all patients. Objective criteria were strictly applied for the 
diagnosis of initial and recurrent VTE, including contrast 
venography and pulmonary angiography if indicated, 
and major bleeding was classified according to widely 
accepted and validated criteria. 
We conclude that arm DVT is a serious complication in 
patients with cancer, with a high recurrence rate despite 
anticoagulant therapy, as well as a high incidence of severe 
bleeding complications. Accordingly, adequate identifica­
tion of patients at risk, effective and safe prophylaxis, and 
early confirmation of diagnosis is warranted.
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проблема тромбоза Глубоких вен у больных 
онколоГическоГо профиля: анализ факторов риска.  
Данные реГистра riete
Цель: обновить базу данных по клиническим характеристикам и течению заболевания у больных с тромбозом глубоких вен 
верхних конечностей (ТГВ) с использованием системы регистра венозного тромбоэмболизма (СРВТ). Методы: СРВТ является 
непрерывной системой регистрации больных с симптомами объективно подтвержденной острой венозной тромбоэмболии. 
Проанализированы клинические характеристики и течение болезни на протяжении месяцев у больных онкологического профиля 
с ТГВ. Результаты: в период декабря 2006 г. были обследованы 14 391 больных с симптоматической объективно подтвержден-
ной острой венозной тромбоэмболией при помощи системы СРВТ. Из 2945 больных с прогрессирующим течением заболевания 
у196 (6,7%) человек выявили ТГВ верхних конечностей: у 104 — ассоциированный с катетером ТГВ. Большинство больных 
с ТГВ верхних конечностей — лица мужского пола в возрасте моложе 65 лет и с низкой частотой дополнительных факторов 
риска или первичного заболевания. У 20 из них (10%) отмечали симптомы эмболии легочной артерии (ЭЛА). Больные получали 
низкомолекулярный гепарин и в начале исследования (94%), и по его окончании (75%). В течение последующих трех месяцев 
у12 больных (6,1%) развился рецидив венозной тромбоэмболии (ВТЭ) (ЭЛА – у 6 больных, ТГВ – у 6 больных), у 8 (4,1%) 
отмечали кровотечение (3 случая с летальным исходом), 43 (22%) пациента умерли. Выводы: данные СРВТ системы показали, 
что ТГВ верхних конечностей является серьезным осложнением у больных, онкологического профиля, сочетающимся с высокой 
степенью развития рецидива и осложнений, сопровождающихся кровотечениями. 
Ключевые слова: рак, катетер, вена, тромбоз, фактор риска.
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